



Aura Biosciences to Participate in Upcoming Investor Conferences

February 26, 2024

BOSTON--(BUSINESS WIRE)--Feb. 26, 2024-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

- **44th Annual TD Cowen Health Care Conference on Monday, March 4, 2024.**
Fireside Chat at 1:30 p.m. ET.
- **Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024.**
Fireside Chat at 3:40 p.m. ET.

The live webcasts of both fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at <https://ir.aurabiosciences.com/events-and-presentations>, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing VDCs, a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting, anti-tumor immunity. Bel-sar is currently in development for ocular cancers, and Aura is enrolling patients in the global Phase 3 trial evaluating first-line treatment of early-stage choroidal melanoma, a vision- and life-threatening form of eye cancer where the standard of care with radiotherapy leaves patients with severe comorbidities, including significant vision loss. Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura’s technology platform, Aura is developing bel-sar more broadly across multiple cancers, including in patients with non-muscle invasive and muscle invasive bladder cancer. Aura is headquartered in Boston, MA.

For more information, visit aurabiosciences.com, or follow us on [X, formerly Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240226370868/en/): <https://www.businesswire.com/news/home/20240226370868/en/>

Investors and Media:

Alex Dasalla
Head of Investor Relations and Corporate Communications
adasalla@aurabiosciences.com

Source: Aura Biosciences Inc.